STOCK TITAN

Cytomx Therapeutics Inc SEC Filings

CTMX NASDAQ

Welcome to our dedicated page for Cytomx Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking R&D swings at a clinical-stage biotech is hard enough—doing it inside CytomX Therapeutics’ two-hundred-plus-page reports can feel impossible. If you have ever typed “Where can I find the CytomX Therapeutics quarterly earnings report 10-Q filing?” or “How do I monitor CytomX Therapeutics insider trading Form 4 transactions?”, you already know the challenge. Stock Titan turns that complexity into clarity, with CytomX Therapeutics SEC filings explained simply.

Our AI reads every submission the moment it lands on EDGAR, then delivers plain-English takeaways you can trust. Need the CytomX Therapeutics annual report 10-K simplified? Prefer the CytomX Therapeutics 8-K material events explained in one paragraph? Looking for the CytomX Therapeutics proxy statement executive compensation table without scrolling? It’s all here—plus real-time alerts that flag CytomX Therapeutics Form 4 insider transactions right as they post.

Because CytomX relies on milestone payments and collaboration revenue, a single footnote can shift valuation models overnight. Stock Titan’s AI highlights those footnotes, compares cash-burn trends, and links trial updates across quarters so you don’t miss a beat. Use the platform to:

  • Compare R&D expense paths quarter-over-quarter through CytomX Therapeutics earnings report filing analysis
  • Track leadership equity grants via CytomX Therapeutics executive stock transactions Form 4
  • Receive push notifications on CytomX Therapeutics Form 4 insider transactions real-time
  • Download clean tables for valuation and diligence models

Understanding CytomX Therapeutics SEC documents with AI means spending minutes—not hours—on the disclosures that drive this pioneering probody technology developer.

Rhea-AI Summary

Biotechnology Value Fund (BVF) and related entities have filed Amendment No. 5 to Schedule 13G for CytomX Therapeutics, Inc. (CTMX). As of the close of business on 9 July 2025, the group collectively holds 5,769,231 common-share equivalents in the form of Tranche 2 warrants that are exercisable at $3.77 per share and expire on 3 July 2026. The warrants include a 9.99 % beneficial-ownership blocker that limits exercise to keep the holder’s ownership below that threshold.

Beneficial ownership is reported on a disaggregated basis: BVF (3.07 M shares; 1.9 %), BVF II (2.35 M; 1.5 %), and Biotechnology Value Trading Fund OS (0.27 M; <1 %). Through control relationships, BVF GP Holdings and BVF Partners L.P. may be deemed to beneficially own 3.3 % and 3.5 % of outstanding shares, respectively. All entities disclaim ultimate beneficial ownership beyond their respective capacities.

The percentages are calculated against a base of 157.54 M common shares outstanding following the issuer’s May 2025 equity offering, plus the warrants counted as if exercised. No holder exceeds the 5 % reporting threshold individually, and the filing is made on Schedule 13G to reflect passive investment intent; the certification confirms the securities were not acquired to influence control of CTMX.

Key takeaways for investors

  • BVF remains a notable but non-controlling holder with a ~3.5 % aggregate economic interest.
  • Exposure is entirely via $3.77 warrants, providing potential upside without current voting power.
  • The 9.99 % blocker limits near-term ownership expansion but allows full exercise should total shares outstanding rise.
  • The amendment updates ownership levels following the issuer’s recent public offering and does not signal activism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Biotechnology Value Fund (BVF) and affiliated entities have filed Amendment 4 to a Schedule 13G disclosing their aggregate beneficial ownership of CytomX Therapeutics, Inc. (NASDAQ: CTMX) as of 30 June 2025.

The filing shows that the BVF complex—comprising eight Delaware and Cayman-based funds and general partners plus founder Mark N. Lampert—collectively controls 11,538,462 common shares, or 6.8 % of CytomX’s outstanding stock. The position is held entirely through two series of cash-settled warrants:

  • Tranche 1 Warrants: 5,769,231 shares, strike $2.73, expire 3 July 2025.
  • Tranche 2 Warrants: 5,769,231 shares, strike $3.77, expire 3 July 2026.

The warrants are subject to a 9.99 % “blocker,” preventing exercise that would take the group’s ownership above that threshold. Current ownership remains below 7 %, therefore none of the warrants are blocked.

Breakdown of key subsidiary holdings:

  • Biotechnology Value Fund L.P.: 6,148,026 shares (3.8 % of class)
  • Biotechnology Value Fund II L.P.: 4,702,892 shares (2.9 % of class)
  • Biotechnology Value Trading Fund OS LP: 541,232 shares (<1 % of class)

BVF GP Holdings LLC (6.4 %) and BVF Partners L.P. (6.8 %) are the primary control entities, with shared voting and dispositive power across the structure. All parties certify the stake is passive and not intended to influence control of CytomX.

The ownership percentages are calculated against 157,544,369 shares reported outstanding in CytomX’s May 13 2025 prospectus plus the warrant shares, where applicable.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Cytomx Therapeutics (CTMX)?

The current stock price of Cytomx Therapeutics (CTMX) is $2.42 as of July 11, 2025.

What is the market cap of Cytomx Therapeutics (CTMX)?

The market cap of Cytomx Therapeutics (CTMX) is approximately 393.9M.

What is the core focus of CytomX Therapeutics?

CytomX Therapeutics is primarily focused on developing conditionally activated antibody therapeutics for oncology, using its proprietary probody technology to target tumors more effectively while reducing off-target toxicity.

How does the probody technology work?

Probody technology involves designing masked biologics that remain inactive in circulation and are activated in the tumor microenvironment, thereby increasing drug concentration at the target site and minimizing systemic side effects.

Which therapeutic areas does CytomX primarily target?

The company focuses on cancer immunotherapy, specifically developing novel treatments that combine the benefits of traditional monoclonal antibodies with enhanced safety profiles achieved through conditional activation.

How do strategic partnerships influence CytomX’s development programs?

Collaborations with industry leaders like Astellas and Merck facilitate the advancement of CytomX’s clinical candidates, allowing for shared expertise and risk, which in turn accelerates the evaluation and validation of its investigational therapeutics.

What differentiates CytomX from traditional antibody therapies?

CytomX’s approach leverages conditionally activated, masked antibodies that are selectively turned on in tumor environments, a method that aims to balance enhanced efficacy with reduced toxicity compared to conventional non-masked antibody therapies.

What role does the tumor microenvironment play in their therapeutic strategy?

The unique biochemical conditions within the tumor microenvironment are key to activating the probody therapeutics, ensuring that the drug's potent activity is localized to the tumor site while preserving healthy tissues.

What are the primary benefits of using probody platform in oncology?

The probody platform offers a way to mitigate widespread drug activity, reducing potential side effects and allowing for focused treatment of cancer cells with improved safety margins.

How is CytomX managing its operational expenses and capital allocation?

The company employs a disciplined approach to cost management by strategically prioritizing its high-potential clinical programs, streamlining operations, and leveraging partnerships to ensure efficient capital allocation for its research and development efforts.
Cytomx Therapeutics Inc

NASDAQ:CTMX

CTMX Rankings

CTMX Stock Data

393.86M
156.11M
1.09%
58.43%
5.86%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO